An evidence-based explanation of how a specific collagen peptide composition was identified, what biological mechanisms have been investigated, and what published human research shows.

Current evidence reviewed: 2024 and 2026 published research on Nextida® GC, with emphasis on the 2026 controlled human study.

Why this Evidence File exists

The word collagen usually brings to mind skin, joints, tendons and bones. That is understandable. Most collagen research has focused on collagen's structural role in connective tissues.

Metabolic research has traditionally looked elsewhere: at the way the digestive system senses nutrients, releases hormones, regulates blood glucose and communicates with the brain. A different line of research began with a simple question: could a carefully selected collagen peptide composition influence some of these natural responses after a meal?

The research that followed did not show that collagen in general has a metabolic effect. Instead, researchers screened different collagen hydrolysates and identified one particular peptide composition with biological activity relevant to incretin signalling. That composition became known as H80 and is now Nextida® GC.

This Evidence File brings the published evidence together in one place. It explains the biology first, then follows the research from laboratory screening through animal studies, an early human proof-of-concept study and the newer 2026 controlled human study.

The biology: what happens after you eat?

A meal does more than provide calories and nutrients. It initiates a coordinated biological response involving the gastrointestinal tract, pancreas, liver and brain.

As nutrients enter the digestive system, specialised intestinal cells release incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones help coordinate the body's response to incoming nutrients.

GLP-1 contributes to glucose regulation by stimulating insulin secretion when glucose is present. It also influences gastric emptying and appetite signalling. GIP is another incretin involved in the physiological response to food.

The important point is that these are normal biological processes. The research behind Nextida® GC is not about introducing a foreign hormone. It investigates whether specific food-derived peptides can influence the body's own incretin response.

Why collagen peptide composition matters

Hydrolysed collagen is collagen that has been broken down into smaller peptides. Those peptides are not all identical. The resulting peptide profile depends on factors including the collagen source and the hydrolysis process.

That matters because biological activity can depend on the particular peptides present, rather than simply the fact that a product is labelled 'collagen'.

In the research programme behind Nextida® GC, scientists screened collagen hydrolysates after simulated digestion and assessed their ability to stimulate GLP-1 secretion in intestinal cell models. In the research reported in 2026, 17 preparations were examined. All stimulated GLP-1 to some degree, but one composition stood out strongly from the reference collagen hydrolysate.

That composition was designated H80 and subsequently became Nextida® GC. The research therefore began not with a claim about collagen as a category, but with the identification of a particular peptide composition.

The first evidence: laboratory and preclinical research

The initial laboratory work provided a biological signal: the selected collagen peptide composition could stimulate GLP-1 secretion in intestinal cell models.

The next question was whether this activity could translate into a physiological response in living systems. The 2024 study investigated H80 in normoglycaemic mice and overweight, prediabetic mice, examining glucose tolerance, insulin, GLP-1 and gastric emptying.

In the mouse experiments, H80 reduced the blood glucose response to an oral glucose challenge and increased active GLP-1. In chronically supplemented prediabetic mice, the researchers also observed slower gastric emptying. These findings provided a plausible biological link between the peptide composition, incretin signalling and post-meal glucose handling.

Animal findings cannot be assumed to predict the same effect in people. Their importance here is that they provided another step between the original cell observation and human research.

The first human evidence: the 2024 proof-of-concept study

The 2024 publication then reported a small human proof-of-concept study. Participants included healthy normoglycaemic people and people with prediabetes. The study found that H80 reduced the postprandial glucose response following a 5 g dose.

This was an important transition in the evidence. The biological activity first observed in laboratory models had now been investigated in humans, with a measurable change in the response to a meal or glucose challenge.

But it was still a proof-of-concept study. A small early human study can establish a signal without answering every question about reproducibility, mechanism or longer-term effects. The next research step therefore needed a stronger clinical design and more detailed measurement of what was happening physiologically.

The 2026 study: testing the mechanism in humans

The most recent published evidence, available online in August 2026, examined whether a preload of the specific collagen peptide preparation could influence post-meal glucose regulation and the biological responses associated with it.

The study included 30 adults: 12 with normal glucose regulation and 18 with prediabetes. Researchers used a randomised, double-blind, placebo-controlled crossover design. Each participant received the collagen peptide preparation and placebo on separate occasions, allowing the researchers to compare responses within the same individual.

Participants consumed 10 g of the collagen peptide preparation 30 minutes before a standardised carbohydrate-rich meal. Researchers then measured blood glucose, insulin, C-peptide, GLP-1 and GIP. They also used an ingestible transit capsule to assess gastric residence.

What did the 2026 study find?

1. Post-meal glucose exposure was lower

The primary glucose outcome was incremental area under the curve (iAUC) over 180 minutes. This captures the overall post-meal glucose response rather than relying on a single measurement.

Following the collagen peptide preload, post-meal glucose exposure was significantly lower than after placebo (P = 0.0178). In practical terms, the overall rise in blood glucose following the standardised meal was smaller.

2. GLP-1 and GIP increased early

The collagen peptide preparation produced an early increase in both GLP-1 and GIP. For both hormones, the reported statistical significance was P < 0.0001.

This is important because the study did not simply observe a change in glucose and speculate about a mechanism. It measured the incretin hormones themselves and found an early hormonal response following the peptide preload.

3. Total insulin exposure did not increase

Researchers also observed an early increase in insulin before the meal. However, total insulin exposure across the full post-meal measurement period was not significantly different between conditions (insulin iAUC, P = 0.8929).

This helps put the glucose finding into context. The study did not show simply that more insulin was released throughout the entire post-meal period. The response involved changes in incretin signalling and the timing of the physiological response.

4. Gastric residence increased in the prediabetes subgroup

Among participants with prediabetes, the collagen peptide significantly increased gastric residence time (P = 0.0436). The reported difference was approximately 37 minutes compared with placebo.

The rate at which food leaves the stomach affects how quickly nutrients reach the small intestine and enter circulation. The gastric finding therefore provides another piece of physiological information that fits with the observed incretin and glucose responses.

Putting the findings together

The value of the 2026 study is not any single measurement. It is the pattern.

A specific collagen peptide preparation was consumed before a meal. Early GLP-1 and GIP responses increased. Post-meal glucose exposure was lower. In participants with prediabetes, gastric residence time also increased. Total insulin exposure over the full post-meal period did not increase.

These observations are consistent with a biological model in which the selected collagen peptides interact with the gastrointestinal system before and during the meal, influencing incretin signalling and the movement of nutrients through the digestive tract.

The study does not establish that every part of this sequence is caused by one individual peptide, nor does it establish a single complete mechanism. The exact peptide composition of Nextida® GC is proprietary, and the researchers have not identified every individual peptide responsible for the observed activity.

What this evidence does—and does not—show

The evidence has progressed beyond a theoretical mechanism. Researchers have identified a specific collagen peptide composition, demonstrated biological activity in laboratory models, observed metabolic effects in preclinical research, reported an early human signal and then examined the response in a controlled human study.

However, the 2026 study measured an acute response to a standardised meal. It does not establish long-term effects on HbA1c, sustained body-weight reduction, diabetes progression or long-term cardiovascular outcomes.

It also does not show that ordinary collagen supplements produce the same response. The research is specific to the collagen peptide preparation that was investigated.

That distinction is central to interpreting the evidence correctly.

Why ingredient identity matters

Two products can both contain hydrolysed collagen while having different peptide profiles. Source material, processing and hydrolysis conditions can influence the resulting composition.

For this reason, evidence relating to Nextida® GC should be understood as evidence about that specific ingredient, not evidence about collagen supplements generally.

Slimsafe® was formulated around Nextida® GC as its single active ingredient. The relevance of the research to Slimsafe comes from the identity of the ingredient inside the product, rather than from a general assumption that all collagen behaves in the same way.

How this supports the Slimsafe® formulation

Slimsafe® sits in the CollagenX portfolio's appetite and metabolic support territory. Its formulation is deliberately simple: one specialised active ingredient, Nextida® GC.

The scientific rationale is therefore straightforward. The ingredient was selected because researchers had investigated its ability to interact with biological processes involved in the response to food, including incretin signalling, gastric transit and post-meal glucose regulation.

The evidence does not mean that Slimsafe® should be viewed as a treatment for diabetes or as a substitute for dietary and lifestyle measures. It means that the ingredient at the centre of the formulation has been studied for a defined biological purpose and that the published research provides evidence for measurable acute physiological responses in humans.

The evidence in perspective

The research programme has followed a logical progression:

·        Different collagen hydrolysates were screened for biological activity.

·        A specific composition, H80, demonstrated particularly strong GLP-1 activity in laboratory models.

·        Preclinical research investigated glucose tolerance, GLP-1, insulin and gastric emptying.

·        A 2024 proof-of-concept human study reported a reduced postprandial glucose response.

·        A 2026 randomised, double-blind, placebo-controlled crossover study measured glucose, incretin hormones, insulin-related markers and gastric residence in humans.

This is why the most useful way to describe the science is not that 'collagen lowers blood sugar'. That statement is too broad. The evidence is more specific: a particular collagen peptide composition has been investigated for its effects on the body's post-meal metabolic response, and controlled human research has demonstrated changes in incretin hormones, gastric residence and post-meal glucose exposure.

You may also find this blog interesting: 

Metabolic Collagen: Why the Next Generation of Collagen Peptides Could Change Weight Management

References

1.      Grasset E, Briand F, Virgilio N, et al. A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans. Food Science & Nutrition. 2024;12(11):9607–9620. doi:10.1002/fsn3.4538.

2.        Specific Collagen Peptides Support Postprandial Metabolic Health by Modulating Incretin Hormones, Gastric Transit, and Glycemic Control in Participants with Normoglycemia and Prediabetes. Current Developments in Nutrition. Published online 8 August 2026. doi:10.1016/j.cdnut.2026.109512.

A note on the evidence

Evidence Files are educational resources designed to explain the science behind CollagenX formulations. They are not scientific papers and do not replace independent medical or nutritional advice. The strength of each statement in this Evidence File reflects the evidence available from the published research cited above.